期刊文献+

非瓣膜病心房颤动患者血小板活化状态的研究

Changes of platelet activity in middle-old aged patients with nonvalvular atrial fibrillation
下载PDF
导出
摘要 目的了解非瓣膜病心房颤动(房颤)患者血小板的活化状态。方法观察92例非瓣膜病持续性房颤患者(房颤组)与60例窦性心律者(对照组)血小板功能状态的分子标记物水平,用酶联免疫吸附双抗体夹心法测定血浆血小板α颗粒膜糖蛋白-140(GMP-140)水平,用放射免疫分析法测定血栓素B2(TXB2)和6-酮-前列腺素F1α(6-k-PGF1α)水平。结果房颤组GMP-140和TXB2水平显著高于对照组,6-k-PGF1α水平显著低于对照组,TXB2/6-k-PGF1α比值也显著高于对照组。调整其他影响因素后,房颤组GMP-140和TXB2水平仍显著高于对照组,6-k-PGF1α水平仍显著低于对照组。GMP-140水平在合并糖尿病和合并高甘油三酯血症的房颤患者进一步升高。结论非瓣膜病房颤患者处于血小板激活状态。 Objective To study the changes of platelet activity in patients with nonvalvular atrial fibrillation. Methods Levels of platelet activity markers were measured in 92 patients aged 45 - 80 with persistent nonvalvular atrial fibrillation (AF group) and 60 patients with sinus rhythm (control group). Enzyme linked immunosorbent assay was used to measure plasma platelet granular membrane protein-140 (GMP-140) and radioimmunoassay was used to measure plasma thromboxane B2 ( TXB2 ) and 6-keto-prostaglandin F1α ( 6-k-PGF1α ). Results The patients in AF group had significantly higher plasma GMP-140 and TXB2 and lower plasma 6-k-PGF1α compared with the patients in control group. The patients in AF group also had significantly higher ratio of TXB2/6-k-PGF1α. Multivariate analysis showed that the differences of GMP-140, TXB2 and 6-k-PGF1α between the 2 groups were not affected by the other factors. In AF group, plasma level of GMP-140 was higher in the patients complicated by diabetes and hypertriglyceridemia. Conclusion The present results indicated that the patients with nonvalvular atrial fibrillation are in the state of platelet activation.
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2006年第5期313-315,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
基金 卫生部保健专项科研基金(2001-012)
关键词 心房颤动 血小板膜蛋白类 血栓烷B2 6-酮前列腺F1α 血小板活化因子 atrial fibrillation platelet membrane glycoproteins thromboxane B2 6-keto-prostaglandin F1 alpha platelet activating factor
  • 相关文献

参考文献8

  • 1Kamath S, Blann AD, Lip GYH. Platelet activation: assessment and quantification[J]. Eur Heart J, 2001, 22: 1561-1571.
  • 2Pongratz G, Pohlmann BM, Henneke H, et al. Platelet activation in embolic and prembolic status of patients with nonrhettmatic atrial fibrillation[J]. Chest, 1997,111:929-933.
  • 3Conway DS, Pearce LA, Chin KS, et al. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors[J]. Circulation,2002,106:1962-1967.
  • 4Goette A, htenson A, Hoffmanns P, et al. Increased expression of Pselectin in patients with chronic atrial fibrillation [ J ]. Pacing Clin Electrophysiol, 2000,23 : 1872-1875.
  • 5Hart RG, Leonard AD, Talbert RL, et al. Aspirin dosage and thromboxane synthesis in patients with vascular disease[J]. Pharmacotherapy, 2003,23: 579-584.
  • 6Lorenzoni R, Lazzerini G, Cocci F, et al. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation(CLAAF) pilot study[J] .Am Heart J,2004,148:e6.
  • 7Panchenko VM, Smoliar MI, Zhivoderov VM.Thromboxane, prostacyclin and platelet factor 4 in patients with atrial fibrillation[J]. Klin Med (Mosk), 1991,69:80-82.
  • 8Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: The seventh ACCP conference on antithrombotic and thrombolytic therapy[J]. Chest,2004,126:429s-456s.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部